Monte Rosa Therapeutics, Inc. (GLUE), a clinical-stage biotechnology company, is scheduled to highlight interim clinical results from the ongoing Phase 1 study of MRT-8102, being developed for the treatment of inflammatory diseases, on January 7, 2026.
The presentation will include interim data from the ongoing Part 3 C-reactive protein (CRP) proof-of-concept cohort in participants with elevated cardiovascular disease risk.
The company will host a live conference call and webcast on Wednesday, January 7, 2026, at 8:00 a.m. ET to reveal the results.
Following the announcement, GLUE surged 8.62% at $17.39 in the after-hours market.
MRT-8102 is an experimental pill designed to break down a protein called NEK7. This helps treat inflammatory diseases caused by problems with certain immune signals like NLRP3, IL-1ß, and IL-6.
The Phase 1 study of MRT-8102 has three parts.
Part 1: Healthy volunteers receive a single oral dose of MRT-8102 or a placebo on Day 1.Part 2: Healthy volunteers receive multiple oral doses of MRT-8102 or a placebo daily for 7 days.Part 3: Participants with cardiovascular risk and high CRP receive multiple oral doses of MRT-8102 or a placebo daily for 28 days. (Source: Clinicalrials.gov).
As part of initiating the Phase 1 study, Monte Rosa planned to establish initial proof of concept for cardio-immunology indications by evaluating changes in C-reactive protein (CRP) and other key inflammatory markers in a cohort of subjects with elevated CRP levels.
The ongoing Phase 1 study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of MRT-8102 in healthy participants and in participants at cardiovascular risk with elevated CRP. The purpose of the study also includes the safety and tolerability of 28-day daily dosing of MRT-8102.
Monte Rosa's proprietary QuEEN discovery platform combines AI-driven chemistry, structural biology, and proteomics to enable the rational design of molecular glue degraders with selectivity. This technology supports a pipeline of Monte Rosa's MGDs, including three candidates currently in clinical development.
GLUE closed Tuesday's trade at $16.01, up 11.18%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.